ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential

Xiang, Hui*; Liu, Qi-Pinguniv three gorges
WORLD JOURNAL OF GASTROENTEROLOGY2022-12-21DOI: 10.3748/wjg.v28.i47.6689
5被引19阅读
引用收藏
分享

摘要

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious threat to global health. SARS-CoV-2 infects host cells primarily by binding to angiotensin-converting enzyme 2, which is coexpressed in alveolar type 2 cells and gut epithelial cells. It is known that COVID-19 often presents with gastrointestinal symptoms and gut dysbiosis, mainly characterized by an increase in opportunistic pathogens and a decrease in beneficial commensal bacteria. In recent years, multiple studies have comprehensively explored gut microbiota alterations in COVID-19 and highlighted the clinical correlation between dysbiosis and COVID-19. SARS-CoV-2 causes gastrointestinal infections and dysbiosis mainly through fecal-oral transmission and the circulatory and immune pathways. Studies have shown that the gut microbiota and its metabolites can regulate the immune response and modulate antiviral effects. In addition, the gut microbiota is closely related to gastrointestinal symptoms, such as diarrhea, a common gastrointestinal symptom among COVID-19. Therefore, the contribution of the gut microbiota in COVID-19 should not be overlooked. Strategies targeting the gut microbiota via probiotics, prebiotics and fecal microbiota transplantation should be considered to treat this patient population in the future. However, the specific alterations and mechanisms as well as the contributions of gut microbiota in COVID-19 should be urgently further explored.

学科与关键词

关键词
COVID-19SARS-CoV-2Angiotensin-converting enzyme 2Gut microbiotaDysbiosisLung
相关
加载中…
  • The New Foe and Old Friends: Are We Ready for Microbiota-Based Therapeutics in Treating COVID-19 Patients?
    Peng, Ye*; Zhao, Jincun; Tun, Hein M.Gastroenterology, 2021, 160(6): 2192-2193.被引 3
  • Antibiotic-Induced Primary Biles Inhibit SARS-CoV-2 Endoribonuclease Nsp15 Activity in Mouse Gut
    Ma, Yao; Luo, Mei; Deng, Yusheng; Yang, Xiaoman; Wang, Xionglue; Chen, Guozhong; Qin, Zixin; Deng, Yun; Nan, Meiling; Chen, Yang; Wang, Peihui; Wei, Hong; Han, Lijuan*; Fang, Xiaodong*; Liu, Zhi*Frontiers in Cellular and Infection Microbiology, 2022, 12: 896504.被引 1
  • Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis
    Wu, Xiaoming; Jing, Haijiao; Wang, Chengyue; Wang, Yufeng; Zuo, Nan; Jiang, Tao*; Novakovic, Valerie A.; Shi, Jialan*Frontiers in Microbiology, 2022, 13: 860931.被引 13
查看全部 →

发表信息

论文状态
公开发表
期刊
WORLD JOURNAL OF GASTROENTEROLOGY
发表日期
2022-12-21
卷期
第 28 卷, 第 47 期
页码
6689-6701
DOI
10.3748/wjg.v28.i47.6689
语言
ENGLISH
期刊等级
3区
成果收录
SCIE

作者

  • X

    Xiang, Hui (通讯) (第一作者)

    univ three gorges

  • L

    Liu, Qi-Ping

    univ three gorges

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417